Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
COYAthis companyCoya Therapeutics, Inc.	$3.04	-4.57×	2.26×	12.21×	-2.37×	45.7%	99.7%	-255.0%	-267.1%	-49.3%	-46.0%	-11.1%	0×	2.21×	0×	8.5×	0.0%	3	8.76	1	D+
CLNNClene Inc.	$4.56	-2.22×	-3.29×	289.36×	-3.38×	-148.3%	78.5%	-11541.5%	-13086.5%	148.8%	-188.6%	-32.1%	-1.23×	-0.75×	-8.61×	0.83×	0.0%	2	-23.05	2	C
CNTXContext Therapeutics Inc.	$0.20	-3.87×	2.31×	0×	-2.05×	231.0%	0.0%	0.0%	0.0%	-59.7%	-65.5%	-18.9%	0×	1.82×	0×	8.52×	0.0%	2	-5.58	3	B
IMMXImmix Biopharma, Inc.	$8.63	-5.88×	1.84×	0×	-2.69×	-63.4%	0.0%	0.0%	0.0%	-31.4%	-31.6%	-14.3%	0.01×	3.14×	0×	10.01×	0.0%	2	35.26	2	C+
MGNXMacroGenics, Inc.	$2.44	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
ORMPOramed Pharmaceuticals Inc.	$3.96	1.86×	0.59×	59×	0.97×	-70.9%	0.7%	-754.4%	3202.5%	32.1%	-6.0%	-9.4%	0×	-0.6×	0×	6.98×	0.0%	3	3.38	5	S-
Peer median	—	-2.22×	1.83×	0.68×	-2.54×	-70.9%	0.7%	-48.7%	0.0%	-31.4%	-33.0%	-18.9%	0×	-0.6×	0×	6.98×	0.0%	2	-4.43	2	—